Solitary fibrous tumor
MONDO:0016238Solitary fibrous tumor (SFT) represents a diverse group of ubiquitous rare spindle cell neoplasms that may be benign or malignant and that most frequently arises from the pleura and peritoneum and rarely from other sites such as head and neck, liver and skeletal muscle. SFT may be clinically asymptomatic or may present with enlarging mass, compressive effects depending on the site involved and rarely with paraneoplastic manifestations (osteoarthropathy or hypoglycemia).
Also known as: SFT, localised fibrous mesothelioma, localised fibrous tumour, localized fibrous mesothelioma, localized fibrous tumor, solitary fibrous tumor, submesothelial fibroma, hemangiopericytoma
1434 clinical trials for this condition and its sub-types, 8 tagged with Solitary fibrous tumor itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Solitary fibrous tumor
-
Hemangiopericytoma, malignant 0 trials
4 sub-types
- Adult malignant hemangiopericytoma 0 trials
- Childhood malignant hemangiopericytoma 0 trials
- Conventional malignant hemangiopericytoma 0 trials
- Malignant mediastinum hemangiopericytoma 0 trials
-
Liver solitary fibrous tumor 0 trials
-
Peritoneal solitary fibrous tumor 0 trials
1 sub-type
-
Pleural solitary fibrous tumor 0 trials
1 sub-type
-
New hope for kids with rare cancers: targeted drug repotrectinib enters trial
Disease control Recruiting nowThis study tests a drug called repotrectinib in children and young adults (up to age 25) with advanced solid tumors, lymphoma, or brain tumors that have specific gene changes (ALK, ROS1, or NTRK1-3). The goal is to find the safest dose and see if the drug shrinks tumors. Particip…
Phase 1/2 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for rare childhood cancer: drug cocktail aims to shrink tumors and prevent return
Disease control Recruiting nowThis study is for children and young adults (up to age 30) with a rare type of soft tissue cancer called non-rhabdomyosarcoma. It tests whether adding the drugs pazopanib and selinexor to standard chemotherapy can improve outcomes. Participants receive treatment tailored to their…
Phase 1/2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug combo aims to outsmart Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests an experimental drug called OKN4395, taken as a pill, alone or together with the immunotherapy pembrolizumab. The goal is to find a safe dose and see if the combination can shrink tumors in people with advanced solid cancers like lung, colorectal, sto…
Phase 1 • Sponsor: Epkin • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New pill shows promise in slowing rare Cancer's growth
Disease control Recruiting nowThis study tests an experimental oral drug called cirtuvivint for people with advanced soft-tissue sarcoma that has not responded to prior treatment. About 25 participants in Spain will take the drug to see if it can stop or slow cancer growth for at least 3 months. The drug targ…
Phase 2 • Sponsor: Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Scientists launch deep dive into rare sarcomas to unlock immune secrets
Knowledge-focused Recruiting nowThis study is collecting tumor and blood samples from 400 people with rare soft tissue sarcomas to learn how their immune system reacts to the cancer. Researchers will also track patients' health over time to see how the disease progresses. The goal is to find clues that could le…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC